University of Groningen

Serum protein markers for the early detection of lung cancer

Broodman, Ingrid; Lindemans, Jan; van Sten, Jenny; Bischoff, Rainer; Luider, Theo M

Published in:
Journal of Proteome Research

DOI:
[10.1021/acs.jproteome.6b00559](https://doi.org/10.1021/acs.jproteome.6b00559)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2017

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Broodman, I., Lindemans, J., van Sten, J., Bischoff, R., & Luider, T. M. (2017). Serum protein markers for the early detection of lung cancer: a focus on autoantibodies. *Journal of Proteome Research*, 16(1), 3-13. <https://doi.org/10.1021/acs.jproteome.6b00559>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies

Ingrid Broodman,[†] Jan Lindemans,[†] Jenny van Sten,[‡] Rainer Bischoff,^{*,§} and Theo Luider[‡]

[†]Department of Clinical Chemistry and [‡]Department of Neurology, Erasmus University Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands

[§]Analytical Biochemistry, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands

ABSTRACT: Lung cancer has the highest mortality rate among cancer patients in the world, in particular because most patients are only diagnosed at an advanced and noncurable stage. Computed tomography (CT) screening on high-risk individuals has shown that early detection could reduce the mortality rate. However, the still high false-positive rate of CT screening may harm healthy individuals because of unnecessary follow-up scans and invasive follow-up procedures. Alternatively, false-negative and indeterminate results may harm patients due to the delayed diagnosis and treatment of lung cancer. Noninvasive biomarkers, complementary to CT screening, could lower the false-positive and false-negative rate of CT screening at baseline and thereby reduce the number of patients that need follow-up and diagnose patients at an earlier stage of lung cancer. Lung cancer tissue generates lung cancer-associated proteins to which the immune system might produce high-affinity autoantibodies. This autoantibody response to tumor-associated antigens starts during early stage lung cancer and may endure over years. Identification of tumor-associated antigens or the corresponding autoantibodies in body fluids as potential noninvasive biomarkers could thus be an effective approach for early detection and monitoring of lung cancer. We provide an overview of differentially expressed protein, antigen, and autoantibody biomarkers that combined with CT imaging might be of clinical use for early detection of lung cancer.

KEYWORDS: antibody, antigen, biomarker, computed tomography (CT) screening, early detection, lung cancer, next-generation sequencing (NGS), proteomics, tumor immunology

LUNG CANCER INCIDENCE AND ETIOLOGY

Lung cancer is the most common cancer type. Worldwide, more than 1.8 million men and women were diagnosed with lung cancer in 2012.^{1,2} In that year, an estimated 1.6 million died of lung cancer, accounting for one-fifth (19%) of all cancer deaths in the world.¹

Cigarette smoking is the most important risk factor for lung cancer and accounts for about 80–90% of cases.^{3,4}

Almost 70% of the people diagnosed with lung cancer are 65 or older. The median age at time of diagnosis is about 70 years.^{5,6} Lung cancer is more common in men than in women. The male to female age-standardized incidence rates ratio is about 60% higher in men.⁴ This high male to female ratio is mainly due to the higher prevalence of cigarette smoking in men than women.⁷

Survival rates of lung cancer patients vary depending on the stage of the cancer at diagnosis. The 5 year survival rate for lung cancer is about 15%.^{4,8} However, the 5 year survival rate may increase up to 49% when lung cancer is diagnosed at an early stage.⁵

TYPES OF LUNG CANCER

Lung cancer, also known as carcinoma of the lung, is a malignant lung tumor formed by uncontrolled cell growth in the tissues

of the lung, usually in the bronchi and the airways of the lungs. This growth may spread to a site distant from the lungs and produce metastatic tumors in brain, bone, liver, or adrenal glands.⁴ Primary lung cancers are carcinomas that start in the lung and are derived from epithelial cells. The two main primary types of lung cancer are non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). About 85% of all lung cancers are NSCLC. The three main subtypes of NSCLC are adenocarcinoma (40%), squamous cell carcinoma (25–30%), and large cell carcinoma (10–15%).⁵

About 10–15% of lung cancers are SCLC. SCLC often starts in the larger airways, the primary (main) and secondary (lobar) bronchi. It is the most aggressive type of lung cancer, grows more quickly than NSCLC, and often metastasizes to other parts of the body early in the development of the disease.⁵ Most of the SCLC patients have widespread metastasis at the time of diagnosis. SCLC is often associated with paraneoplastic

Special Issue: The Immune System and the Proteome 2016

Received: June 19, 2016

Published: October 21, 2016

syndromes (PNS).⁵ The 5 year survival for SCLC (6%) is lower than that for NSCLC (21%).^{5,6} Nearly all cases of SCLC are due to cigarette smoking.^{4,5,9}

■ DIAGNOSIS AND STAGING

Lung cancer tumors usually grow for many years without causing any signs or symptoms during the early stages of the disease. About 5–10% of the lung cancer patients are diagnosed with lung cancer at an early stage when still asymptomatic during a physical examination for an unrelated medical problem or after a routine chest X-ray. Unfortunately, most symptomatic lung cancer patients are diagnosed with lung cancer at an advanced stage. Chest X-ray only produces a flat, 2D image of the lungs and usually detects large tumors but may miss smaller or hidden tumors and does not exclude lung cancer.^{10,11} Computed tomography (CT) uses a combination of many X-ray images taken in a circle around the chest and computer technology to produce highly detailed 3D images of the internals of the lungs. CT scans are able to detect smaller tumors than routine chest X-ray analyses and also determine the size, shape, and location of the tumor because of the 3D measurement. The final determination of whether a tumor is malignant and definitive diagnosis of the type of lung cancer can only be made by examining of a tissue sample by a pathologist. This tissue sample can be obtained by bronchoscopy, sputum cytology, or fine needle aspiration biopsy.^{4,5}

Lung cancer staging is based on a system that describes the growth and extent of spread of the cancer to other parts of the body. The TNM system classifies patients in five stages: 0 (in situ), I, II, III, or IV. Patients with a higher stage number have a poorer prognosis and lower survival rate.¹²

■ LUNG CANCER SCREENING

The purpose of lung cancer screening is to detect lung cancer at an early and still curable stage to improve the survival rate of lung cancer patients. Survival rate improves significantly with early detection of the disease, with a respective 5 year survival

rate increasing from 2 to 7, 19, 25, 36, and 43% for stages IV, IIIB, IIIA, IIB, IIA, and IB and to 50% for stage IA.¹² Surgery offers the best chance to cure early-stage NSCLC patients. Because these patients are usually asymptomatic, only 15% of all diagnoses of lung cancer are from stage I.⁴ In contrast, CT screening detected 48–85% of lung cancers at stage I.^{11,13} Therefore, CT screening is performed on apparently healthy, asymptomatic people at high risk of lung cancer such as current smokers and former smokers.

■ RANDOMIZED SCREENING STUDIES

Randomized screening studies for early detection of lung cancer in high-risk individuals are ongoing. An overview of the main large-scale lung cancer screening studies is presented in Table 1. These studies compare CT screening with chest X-ray or usual care. The aim of these lung cancer screening studies is to reduce mortality by 20–25% by detection at an early and still curable stage. Three trials in Europe, the DANTE (Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays), DLCST (Danish Lung Cancer Screening Trial), and MILD (Multicentric Italian Lung Detection) trials, reported no significant reduction in lung cancer mortality.^{14–18}

The largest study, the NLST (U.S. National Lung Screening Trial) study, reported a significant lung cancer mortality reduction of 20.3% in high-risk individuals who were screened annually with CT compared with those who were screened annually by chest X-ray.^{19,20} At present, the NELSON, ITALUNG, LUSI, and the UKLS screening studies (Table 1) are still ongoing. When data of all randomized screening studies become available, a definitive conclusion of the effectiveness of CT screening can be drawn.

■ THE NELSON STUDY

The NELSON study (Nederlands-Leuven Longkanker Screeningsonderzoek), a Dutch-Belgian Lung Cancer Screening trial, is the world's second largest randomized lung cancer computer tomography screening trial and differs from the NLST study by

Table 1. Main Large-Scale Randomized Controlled Lung Cancer Screening Trials^a

trial	initiation/completion	N	design	screens	♂ (%)	age (y)	pack (y)	quit (y) ^b
DANTE ^{15,16,21}	2001	2472	CT vs none	5	100	60–74	≥20	<10
Italy	2009							
NLST ^{19,20}	2002	53 454	CT vs CXR	3	59	55–74	≥30	<15
USA	2011							
ITALUNG ²²	2004	3206	CT vs none	4	65	55–69	≥20	<10
Italy	ongoing							
NELSON ^{23–25}	2004	15 822	CT vs none	5	84	50–75	≥15 ^c	≤10
Netherlands/Belgium	ongoing							
DLCST ^{17,26}	2004	4104	CT vs none	5	55	50–70	≥20	<10
Denmark	2011							
MILD ¹⁸	2005	4099	CT vs none	5	66	≥49	≥20	<10
Italy	2012							
LUSI ^{27,28}	2007	4052	CT vs none	5	65	50–69	≥15 ^c	≤10
Germany	ongoing							
UKLS ^{29,30}	2011	4055	CT vs none	pilot study	75	50–75	NA ^d	NA
United Kingdom	ongoing							

^aCXR, chest X-ray; DANTE, Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays; DLCST, Danish Lung Cancer Screening Trial; ITALUNG, Italian lung study; CT, computed tomography; MILD, Multicentric Italian Lung Detection trial; N, patient number; NA, not applicable; NELSON, Dutch-Belgian Lung Cancer Screening Trial (Dutch acronym); NLST, National Lung Screening Trial; LUSI, German Lung Screening and Intervention trial; UKLS, U.K. Lung Screening trial; y, years; ♂, male. ^bQuit smoking. ^cInclusion criteria ≥15 cigarettes per day for 25 y or ≥10 cigarettes per day for 30 years. ^dInclusion criteria ≥5% risk of lung cancer in 5 y.

screening interval, referral policy, and a control arm wherein individuals receive no screening (usual care).^{25,31} The NELSON trial started in 2003. The main purpose of the trial was to investigate whether CT screening leads to a reduction of lung cancer mortality of at least 25% at 10 years of follow-up in a high-risk population. Current or former smokers between 50 and 75 years of age and with a smoking history of at least 15 cigarettes per day for at least 25 years or at least 10 cigarettes per day for at least 30 years were included in the trial. A total of 15 822 participants were randomized (1:1) to a screen or a control arm. The screen arm received CT screening at baseline (first screening round), 1 year later (second screening round), 3 years later (third screening round), and 5.5 years later (fourth screening round), whereas the control arm received no CT screening.²³ Screening results were considered positive for (part) solid lung nodules with a volume of $>500 \text{ mm}^3$ ($>9.8 \text{ mm}$ in diameter) and indeterminate for (partly) solid lung nodules with a volume of 50 to 500 mm^3 (4.6 to 9.8 mm in diameter). Participants with an initial indeterminate screening result received a follow-up CT scan 3 months later to classify their final screening test result as negative or positive based on nodule volume doubling time (VDT).^{24,32} If the nodule had a VDT of <400 days, the final screening result was considered positive. Participants with a positive screening result were referred to a pulmonologist for a diagnostic follow-up according to the national guideline.³³ If lung cancer was diagnosed, the participant was offered treatment and went off screening. Participants with a negative screening result re-entered the trial and underwent a second-round CT scan 12 months later.

The first three screening rounds resulted in 493 positive results, and 200 (40.6%) participants were diagnosed with lung cancer.³¹ Lung cancers in the NELSON trial were more frequently detected at an early stage (70.8% stage I) than at an advanced stage (8.1% stage IIB-IV) compared with other screening trials.^{24,25,31} While the NLST defined any solid nodule with a diameter $\geq 4 \text{ mm}$ as a positive screening result,^{19,20} the NELSON trial considered only solid lung nodules with a volume $>500 \text{ mm}^3$ ($>9.8 \text{ mm}$ in diameter) or VDT < 400 days as a positive screening result. By using these more stringent criteria, the positive predictive value was higher in the NELSON trial (40.6%) than in the NLST trial (3.6%). Consequently, the percentage of false-positive results was substantially lower in the NELSON trial (59.4%) than in the NLST (96.4%) trial.^{19,25,31} Lung cancer mortality results of the NELSON trial are upcoming. The first results on mortality reduction after 10 year follow-up are expected in 2016.

More than 6600 serum samples of the NELSON trial were collected at baseline. Because the NELSON trial can provide prospectively collected samples at baseline of patients with early stage lung cancer, matched with healthy smoker controls, as well with subjects with benign pulmonary nodules, the well-controlled population of the NELSON trial constitutes an ideal set for the design of a case-control study on early lung cancer biomarker discovery.

■ BIOMARKERS

There is a medical need for additional biomarkers for early detection of lung cancer, as CT screening leaves 15–52% of cases undetected at baseline.^{11,13} Furthermore, CT screening has a high rate of false-positive rate due to the high prevalence of benign pulmonary nodules in the population. This results in unnecessary follow-up CT scans, additional tests, biopsies, or even surgery. In the NLST, 24% of subjects with benign

nodules underwent an unnecessary surgical procedure (thoracotomy, thoracoscopy, or mediastinoscopy).¹⁹ These invasive follow-up procedures are costly and may harm patients.^{34,35} Alternatively, false-negative and indeterminate results may harm patients due to the delayed diagnosis and treatment of lung cancer.

Biomarkers in blood could be a noninvasive, cost-effective tool to stratify individuals at high risk of lung cancer who would benefit from CT screening and guide subsequent therapy. These biomarkers may be used for early diagnosis, optimal treatment selection, and prognosis. They may not only reduce the number of unnecessary invasive procedures but also lead to the earlier resection of malignant nodules, which will substantially improve the prognosis of the patient. Unfortunately, there is still no clinically relevant blood biomarker available for lung cancer, although various groups have proposed proteins, mostly in panels of antigens or autoantibodies. In searching for a clinically relevant biomarker, it is vital to understand the biological processes of lung cancer. Lung cancer cells have defects in their regulatory processes that maintain normal cell proliferation and homeostasis. Critical changes in their cell physiology lead to cancer growth. Lung cancer cells are insensitive to growth-inhibitory signals and show escape from apoptosis, unlimited replication, sustained angiogenesis, tissue invasion, and metastasis.³⁶ Transformation from a normal to a malignant lung epithelial cell arises after a series of genetic and epigenetic changes, eventually leading to invasive lung cancer by clonal expansion.³⁷ The molecular composition of lung cancer is complex and heterogeneous, which leads to variable biological, histological and clinical presentations. Various oncogenes, tumor suppressor genes, signaling pathway components, and other cellular processes are involved in the molecular pathogenesis of lung cancer.^{4,38} These molecular processes can lead to the release of various lung cancer associated components, which are not necessarily related to each other, such as tumor DNA, tumor cell fragments, and various mutated or overexpressed proteins into body fluids. Therefore, identification of these lung-cancer-associated components in body fluids as potential biomarkers is a way to detect lung cancer at an early stage and allow more appropriate treatment at that early stage, resulting in a better prognosis. Serum or plasma are considered the most suitable body fluid derivatives for biomarker discovery and diagnosis because they form a minimally invasive and easily accessible source.

■ LUNG-CANCER-ASSOCIATED PROTEINS

Lung cancer is often associated with the differential expression of several proteins, which may be potential biomarkers for lung cancer. Table 2 represents a selection of lung cancer-associated proteins as potential blood-based biomarkers for lung cancer that have been described in literature.

Well-known and clinically used lung cancer protein biomarkers in serum are carcinoembryonic antigen (CEA), CYFRA 21-1 (cytokeratine 19 fragment), neuron-specific enolase (NSE), progastrin-releasing peptide (ProGRP), and squamous cell carcinoma antigen (SCCA). Although these proteins are elevated in serum of a fraction of lung cancer patients, they are not sensitive or specific enough to detect lung cancer in a clinically relevant way or to have enough value as biomarker for the diagnosis of asymptomatic patients with lung cancer.^{49,50}

Lung tumor cells may secrete or release small amounts of tumor-associated proteins at an early stage of lung cancer. Detection of these lung cancer-associated proteins in biological

Table 2. Characteristics and Performance of Blood-Based Proteins as Potential Biomarkers for Lung Cancer^{a,b}

reference	proteins	N	remarks subjects	stage (%)					sensitivity (%)	specificity (%)	AUC	method
				I	II	III	IV	Tx				
Li et al. ³⁹	13 peptide panel	143	D, IPNs ^c	-	-	-	-	100	93	45	0.82	MRM-MS
		104	V, IPNs ^c	-	-	-	-	100	90	27	0.60	
Patz et al. ⁴⁰	CEA, AAT, SCCA ^d	509	D, PNs	41	13	26	16	4	82	84	NA	LCBA
		399	V, PNs	46	18	21	13	2	80	89	NA	
Pecot et al. ⁴¹	clinical data + CT data + MALDI-MS signature ^e	100	IPNs ^f	-	-	-	-	100	NA	NA	0.57	MALDI-MS
									NA	NA	0.67	
									NA	NA	0.72	
Bigbee et al. ⁴²	10 protein panel	60	NSCLC, SC	-	-	-	-	100	73	93	NA	Luminex
Diamandis et al. ⁴³	Penatrxin-3	383	LC, SC	14	2	4	2	78	37	90	0.60	ELISA
Takano et al. ⁴⁴	Nectin-4	295	NSCLC, HC	27 (I-IIIa)		73 (III-B-IV)		-	54	98	NA	ELISA
Ostroff et al. ⁴⁵	12 protein panel	985	D, NSCLC, SC	47	15	38	0	-	91	84	0.91	Aptamers
		341	V, NSCLC, SC	49	14	35	2	-	89	83	0.90	
Patz et al. ⁴⁶	CEA, RBP4, AAT, SCCA	100	D, LC, HC	40	4	30	26	-	89	85	NA	ELISA
		97	V, LC, HC	33	6	39	22	-	78	75	NA	
Yildiz et al. ⁴⁷	MALDI-MS signature ^e	182	D, NSCLC, SC	39 (ES)		61 (LS)		-	67	89	0.82	MALDI-MS
		106	V, NSCLC, SC	40 (ES)		60 (LS)		-	58	86	0.82	
Gao et al. ⁴⁸	CRP, SAA, MUC1	80	LC, SC	-	-	-	-	100	71	93	NA	protein microarray

^aNote: Data are listed by most recent publication first (2013–2005). ^bI, stage I; II, stage II; III, stage III; IV, stage IV; AUC, area under the curve; D, discovery set; ELISA, enzyme-linked immunosorbent assay; ES, early stage: NSCLC I, II and limited SCLC; HC, healthy controls; IPNs, indeterminate pulmonary nodules; LC, lung cancer (NSCLC and SCLC); LCBA, lung cancer biomarker (Immuno)assay; LS, late stage: NSCLC III, IV and extensive SCLC; MRM-MS, multiple-reaction-monitoring mass spectrometry; MS, mass spectrometry; N, patient number; NA, not applicable; PNs, benign and malignant nodules; SC, smoking controls; Tx, tumor stage unknown (or not described), V, validation set. ^cNodule size 10–20 mm. ^dLogistic regression model based on LBCA data and nodule size. ^eSignature of seven features. ^f5–20 mm.

samples has been proposed to support early diagnosis, prognosis, and optimal treatment of lung cancer. However, the large dynamic range of other proteins in blood-derived samples, which extends over 10 orders of magnitude, and the high abundance of albumin (55%) in serum or plasma is a major problem to detect these low-abundant proteins by liquid chromatography–mass spectrometry.⁵¹ Depletion of high-abundant proteins or targeted enrichment of lung-cancer-associated proteins are the main strategies to overcome this problem and to enhance the detection of these low-abundant proteins. New DNA-based aptamers have been developed that contain chemically modified nucleotides that bind to different low-abundant proteins with high affinity. Ostroff et al. used an aptamer-based proteomic assay in a multicenter case-control study of 291 NSCLC cases and 1035 smoking controls.⁴⁵ They developed a panel of 12 proteins (cadherin-1, CD30 ligand, endostatin, HSP90 α , LRIG3, MIP-4, pleiotrophin, PRKCI, RGM-C, SCF-sR, sL-selectin, and YES) that was able to distinguish 213 NSCLC cases (62% stage I–II) from 772 controls with 91% sensitivity and 84% specificity. This panel was tested on a validation set consisting of 78 NSCLC cases (63% stage I–II) and 263 controls, including patients with COPD and benign nodules reaching a sensitivity of 89% at a similar specificity of 83% and an AUC of 0.90. The reason that this panel is not clinically implemented might be because sensitivity and specificity are still too low.

Li et al. used immunoaffinity columns for the depletion of high-abundant proteins. They developed and validated a 13-protein blood-based classifier using multiple-reaction-monitoring mass spectrometry (MRM-MS) in a retrospective study consisting of 52 NSCLC and 52 benign controls. Their classifier distinguished benign from early-stage (IA) NSCLC nodules with a sensitivity of 90% but quite low specificity of 27%.

Table 2 gives an overview of different discovery and validation studies by various research groups. Unfortunately, none of these studies reaches overall sensitivities and specificities to reliably discriminate lung cancer patients from controls, notably for early-stage lung cancer. In addition, most of the proposed lung cancer proteins were not validated between lung cancer cases and controls that were matched for smoking habit, which is the most relevant group for screening purposes. None of the proteins in Table 2 is currently in use or developed as a biomarker for the early detection of lung cancer.

■ IMMUNOLOGICAL BIOMARKERS

The presence of tumor cells can activate the immune system to respond to tumor-specific antigens or to tumor-associated antigens.^{52,53} Tumor-specific antigens (TSAs) are only expressed in tumor cells, whereas tumor-associated antigens (TAAs) are expressed differently by tumor cells and normal cells. The immune system not only protects the host against the development of

primary tumors but may also, strangely enough, promote development of primary tumors. This process, also known as cancer immunoediting, consists of three phases: elimination, equilibration, and escape. Immunosurveillance occurs during the elimination phase, during which the immune system recognizes tumor cells as foreign cells and tries to eliminate them. Tumor cells that survive this phase enter into the equilibrium phase. In the equilibrium phase, tumor cells are mutated to tumor cell variants with increased resistance to immune attack. The equilibrium phase is assumed to be the longest of the three phases and may continue for several years. Tumor cell variants start to grow in an uncontrolled manner and eventually will be detected in the escape phase.^{54,55} These tumor cells express TAAs that distinguish them from normal cells. Most of the TAAs are overexpressed, mutated, misfolded, or aberrantly processed proteins that initiate an autoreactive immune response.^{52,56,57} Post-translational modifications (PTMs) of TAAs, such as acetylation, glycosylation, oxidation, phosphorylation, and proteolytic cleavage, may contribute to the immune response by creating a neo-epitope or by improving self-epitope presentation and affinity to the major histocompatibility complex (MHC) or the T-cell receptor.^{52,56,58} Identification of tumor-associated antigens and autoantibodies to these antigens may provide an opportunity for early detection of lung cancer.⁵⁹

■ ANTIBODIES AS BIOMARKERS

Autoantibodies to TAAs may be potential biomarkers for early detection of lung cancer. First, autoantibodies may be detectable in the asymptomatic stage of lung cancer, up to 5 years prior to detection by CT screening.^{60,61} Second, in contrast with antigens, autoantibodies are stable and persist in serum for a relatively long period of time at rather high levels,⁵² while tumor-associated antigens may only occur transiently at very low levels due to temporary changes in only a few (pre)neoplastic cells. However, the immune system is very sensitive in detecting these very low levels of TAAs and may respond by producing high-affinity T cells and autoantibodies.⁶² Such an autoantibody response to a tumor-associated antigen may endure over years. Thus autoantibodies may be more easily detectable at an earlier stage than their corresponding TAAs.

Human IgGs are large molecules (~150 kDa) and composed of four polypeptide chains, two identical heavy chains (50 kDa) and two identical light chains (25 kDa). Each light chain has a variable (V_L) and constant (C_L) region. The heavy chains have three different constant regions (C_{H1} , C_{H2} , and C_{H3}) and one variable region (V_H). The first constant region and variable region of the heavy chain, together with the constant and variable part of the light chain, form the antigen binding fragment (Fab). The other two constant regions (C_{H2} and C_{H3}) of the heavy chain form the Fc fragment. Three hyper-variable complementarity-determining regions (CDR1, CDR2, and CDR3) in the variable regions of the heavy and light chains form the antigen-binding site. All CDRs in combination determine the specificity of the immunoglobulin to the antigen. During B-cell development and maturation, V, D, and J germline genes are rearranged to form a specific VDJ germline combination. These rearranged genes further diversify by somatic hypermutations to increase antibody affinity.^{63–67} In both light and heavy chains, the diversity of CDR3 is even further enhanced by insertions and deletions of nucleotides. The high diversity of CDR3 makes it the key part of antigen recognition.

It is the region that most directly interacts with the antigen.⁶⁸ The estimated potential diversity in immunoglobulins ranges from 10^{13} to more than 10^{50} .^{66,69} Despite this large range, there is evidence of a repertoire bias, which means that specific germline genes are preferred in the repertoire of immunoglobulins during the immune response to a particular antigen.^{70,71} Antigen-specific immunoglobulin sequences may thus be shared among different lung cancer patients and could serve as biomarkers for lung cancer.

■ LUNG-CANCER-ASSOCIATED AUTOANTIBODIES

During tumor development, lung cancer patients produce specific autoantibodies to TAAs that are potential biomarkers for lung cancer. Table 3 represents a list of autoantibodies to TAAs as potential blood-based biomarkers for lung cancer that have been described in literature.

Although autoantibodies are an active area of research, this work has not yet led to clinically relevant molecular biomarkers. While all of these studies reported autoantibodies to TAAs, none of the proposed autoantibodies found application as biomarker in the clinic. These autoantibodies studies have limitations. First, most of the studies described in Table 3 lack adequate clinical validation. Second, most proposed markers are not specific for lung cancer. For instance, Annexin, CAGE, CEA, HER2, MUC1, NYESO-1, and p53 also arise in other cancers and autoimmune diseases. Furthermore, because of the heterogeneity of lung cancer, it is not likely that an autoantibody to any single tumor-associated antigen will detect all types of lung cancer. Because different target antigens are involved in the immune response to the different tumors, it is more likely that autoantibodies to an antigen panel will detect the different types of lung cancer. The *EarlyCDT-Lung* is currently used as an aid to risk assessment and the early detection of lung cancer in high-risk patients. This blood test measures autoantibodies to a panel of seven TAAs (p53, NY-ESO-1, CAGE, GBU4–5, SOX2, HuD, and MAGE A4) and was validated in large cohorts including early- and late-stage NSCLC and SCLC. This autoantibody panel showed an overall specificity of 91% but a rather low sensitivity of 37% in NSCLC and 55% in SCLC (Table 3), respectively.^{61,74,80–82,88}

Another limitation of most methods in Table 3 is that the antigen or antigen panel must be known at the start of the study. Therefore, the development of a sensitive and specific autoantibody detection method that does not require prior knowledge of the antigens offers opportunities to explore the complete inventory of autoantibodies and possibly the corresponding tumor-associated antigens.

To reach the highest sensitivity and specificity and to cover the histological heterogeneity of lung cancer, we propose that a panel of peptide sequences derived from the antigen-binding site of autoantibodies has potential as a screening test for early-stage lung cancer. While antibody diversity is huge, selection pressure during B-cell development may restrict the antibody diversity. Antibodies are subjected to selection pressure after rearrangement and affinity maturation.^{70,71} Different studies have demonstrated that it is possible to identify similar or identical autoantibody sequences among different individuals.^{93–97} Specific sequences of high-affinity antibodies can be expressed in response to low levels of tumor-associated antigens in early-stage lung cancer and may serve as biomarkers for the early detection of lung cancer.

In initial studies, we were able to detect early-stage lung cancer with an antibody-derived peptide panel with sensitivities

Table 3. Characteristics and Performance of Blood-Based Autoantibodies to TAAs as Potential Biomarkers for Lung Cancer^{a,b}

reference	antibodies to TAAs	N	remarks subjects	stage (%)					sensitivity (%)	specificity (%)	AUC	method
				I	II	III	IV	Tx				
Wang et al. ⁷²	5 AABs panel ^c	264	LC, SC	-	-	-	-	100	30	89	NA	ELISA
	5 AABs panel ^d	307	LC, BNs	-	-	-	-	100	30	88	NA	
	NY-SO-1 (and CEA, CA125, CYFRA 21-1) ^e	230	D, NSCL-C, SC	77	20	3	0	-	74	80	0.81	Luminex
Doseeva et al. ⁷³		150	V, NSCL-C, SC	32	35	20	13	-	77	80	0.85	
	6 AABs panel ^f	752	LC, SC	39	11	21	15	13	46	83	NA	ELISA
	7 AABs panel ^g	847	LC, SC	39	11	21	15	13	37	91	NA	
Jia et al. ⁷⁵	p53, NY-ESO-1, Livin, Ubiquilin, BIRC, p62, PRDX	98	LC, SC	-	-	-	-	100	80	60	0.82	Luminex
Wang et al. ⁷⁶	ANXA1IgG	499	NSCLC, SC	45	19	32	4	-	24	90	0.64	ELISA
	DDXS3IgG	499	NSCLC, SC	45	19	32	4	-	14	90	0.52	
	9 marker panel	200	D, AAH, SC	-	-	-	-	100 ^h	92	90	0.87	phage-display + protein microarray
Lowe et al. ⁷⁷		300	V, AAH, SC	-	-	-	-	100 ^h	82	70	0.81	
	13 marker panel	200	D, SCD, SC	-	-	-	-	100 ^h	98	96	0.96	
		300	V, SCD, SC	-	-	-	-	100 ^h	86	78	0.88	
Zhang et al. ⁷⁸	Anti-p16 IgA	497	NSCLC, SC	44	19	33	4	-	10	90	0.46	ELISA
	Anti-p16 IgG	446	NSCLC, SC	47	17	32	4	-	20	90	0.57	
	6 scFv panel IgM	43	NSCLC, SC	86	14	0	0	-	80	87	0.88	FMAT
Pedchenko et al. ⁷⁹	Anti-CD25	486	NSCLC, SC	45	18	33	4	-	35	90	0.70	ELISA
		776	LC, SC	-	-	-	-	100	40	82	NA	LLC-LIMS
	7 AABs panel ^g	836	LC, SC	-	-	-	-	100	47	90	NA	
Chapman et al. ⁸⁰	p53, NY-ESO1, CAGE, GBU4-5, Annexin I, SOX2 ^f	1,254	LC, SC	60 (ES)	26 (LS)	14	34	87	NA	ELISA		
	p53, NY-ESO-1, CAGE, GBU4-5, Annexin I, SOX2 ^f	481	D, LC, SC	12 (ES)	70 (LS)	18	39	89	0.63	ELISA		
		538	V, LC, SC	63 (ES)	10 (LS)	27	37	90	0.64			
Rom et al. ⁸³	c-myc, Cyclin A, Cyclin B1, Cyclin D1, CDK2, survivin	194	LC, SC	-	-	-	-	100	81	97	0.91	ELISA

Table 3. continued

reference	antibodies to TAAs	N	remarks subjects	stage (%)						sensitivity (%)	specificity (%)	AUC	method
				I	II	III	IV	Tx					
Farlow et al. ⁸⁴	IMPDH, Ubiquitin, phosphoglycerate mutase, Annexin I, Annexin II, HSP70–9B	196	NSCLC, SC	66	13	18	3	-		95	91	0.97	Luminex Immunoassay
Yao et al. ⁸⁵	DKK1	180	NSCLC, HC	-	-	-	-	100		62	84	NA	ELISA
Wu et al. ⁸⁶	OLFM1	180	NSCLC, HC	-	-	-	-	100		92	92	0.96	phage display + ELISA
Leidinger et al. ⁸⁷	1827 peptide clones	127	LC, HC	47	4	38	4	7		98	97	0.81	phage-display
Murray et al. ⁸⁸	p53, NY-ESO-1, CAGE, GBU4–5, Annexin I, SOX2 ^f	481	LC, SC	12 (ES)	70 (-L, S)	18	34	91		NA	ELISA		
Qiu et al. ⁸⁹	Annexin I, LAMR1, 14–3–3 theta	170	NSCLC, SC	-	-	-	-	100 ^f		51	82	0.73	protein micro array
Leidinger et al. ⁹⁰	20 peptide clones	79	NSCLC, HC	46	31	15	3	5		93	93	0.98	phage-display
Chapman et al. ⁶¹	p53, NY-ESO-1, CAGE, GBU4–5, c-myc, HER2, MUC1	154	LC, HC	5	4	15	37	39		76	92	NA	ELISA
Pereira-Faca et al. ⁹¹	14–3–3 theta, Annexin I, PGP 9.5	37	LC, SC	-	-	-	-	100 ^f		55	95	0.84	Western blot + protein microarray
Zhong et al. ⁶⁰	Paxillin, SEC15L2, BAC cloneRP-11-499F19, XRCC5, MALAT1	46	D, NSCLC, SC	100	0	0	0	-		91	91	0.99	phage-display
Yaghashi et al. ⁹²	Survivin, Livin	102	V, NSCLC, SC	13 ^j /68	15 ^j	13 ^j	4 ^j	-		80 ^j /83	88	NA	
		38	D, LC, HC	11	5	30	54	-		71	100 ^h	NA	ELISA

^aNote: Data are listed by most recent publication first (2016–2005). ^bI, stage I; II, stage II; III, stage III; IV, stage IV; AABs, tumor-associated autoantibodies; AAH, atypical adenomatous hyperplasia (preneoplastic adenocarcinoma); AUC, area under the curve; BNs, benign pulmonary nodules; D, discovery set; ELISA, enzyme-linked immunosorbent assay; ES, early stage; NSCLC I, II and limited SCLC; FMAT, fluorometric microvolume assay technology; HC, healthy controls; LC, lung cancer (NSCLC and SCLC); LLC-LIMS, *Early*CDT-Lung test based on ELISA; LS, late stage; NSCLC III, IV and extensive SCLC; N, patient number; NA, not applicable; SC, smoking controls; SCD, squamous cell carcinoma dysplasia (preneoplastic squamous cell carcinoma); scFv, single chain fragment variable antibodies; TAAs, tumor-associated antigens; Tx, tumor stage unknown (or not described), V, validation set. ^c5 AABs panel to TTC14, BRAF, ACTL6B, MORC2, and CTAG1B. ^d5 AABs panel to keratin 8 (type II), TTC14, Kruppel-like factor 8, BRAF, and tousel like kinase 1. ^eMeasurement of antigen panel: CEA, CA125, CYFRA 21-1. ^fA positive test result for the 6 AABs panel was defined as a positive autoantibody response to at least one of the 6 TAAs in the panel: p53, NY-ESO-1, CAGE, GBU4-5, Annexin I, and SOX2 (*Early*CDT-Lung). ^g7 AABs panel: p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4 (new *Early*CDT-Lung). ^hPreneoplastic samples. ⁱPreclinical samples within 1 year before diagnosis. ^jPreclinical samples 1–5 years before diagnosis.

of 96 and 84% and specificities of 100 and 90% in a discovery set and a validation set, respectively, at baseline CT screening.⁹⁸ This work indicates that specific antibodies are present at an early disease stage and that a panel of antibodies may be able to detect lung cancer at an earlier stage than CT screening. Autoantibody profiling has the potential to be a tool for early detection when incorporated into a comprehensive screening strategy, provided that technical challenges of de novo sequencing of CDRs based on high-resolution MS/MS spectra can be overcome.

CONCLUSIONS AND FUTURE PERSPECTIVES

There is a medical need for blood-derived biomarkers that, in combination with CT imaging, can detect lung cancer earlier in individuals at high risk. In a complex and heterogeneous disease like lung cancer, it is likely that only a panel of biomarkers will achieve the necessary sensitivity and specificity. A number of studies have attempted to discover and in certain cases validate such biomarker panels (see Table 2). Panels have been derived from common plasma/serum proteins such as AAT, CRP, or SAA that are related to the acute-phase response or from well-known tumor markers like CEA or SCCA. None of these panels reached sufficient sensitivity or specificity for clinical use, and most have not been validated in large independent cohorts. There is thus a need for new approaches.

Autoantibodies against TAAs are of interest as a potential source of biomarkers because they allow monitoring the immunological response at a very early stage of cancer development. In addition, autoantibodies are more stable in serum than most other proteins and tumor-derived DNA. Table 3 gives an overview of autoantibody-based approaches toward biomarkers for lung cancer. While promising, it is fair to say that none of these approaches has delivered better biomarker panels. It is thus necessary to move beyond quantifying autoantibodies using immunoassays or display techniques to methods that focus directly on the regions that are related to the recognition of tumor-associated antigen, the CDRs. The combination of top-down (protein-based) and bottom-up (peptide-based) proteomics using high-resolution mass spectrometry allows for identification of antigen-binding sites in antibodies and thereby facilitates the de novo sequencing of CDRs.^{99,100} The combination of proteomics and genomics (proteogenomics) further facilitates this approach by opening the opportunity to identify CDR-derived peptides in patient-derived genomic databases.^{101–104} Whether such combined, personalized approaches will be successful in diagnosing lung cancer at an earlier stage and in prognosticating tumor development and response to therapy remains to be seen and is the focus of ongoing large-scale studies.

AUTHOR INFORMATION

Corresponding Author

*E-mail: r.p.h.bischoff@rug.nl. Phone: +31-(0)6-52 000 506.

Notes

The authors declare no competing financial interest.

REFERENCES

(1) Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed 30 May 2015).

(2) Torre, L. A.; Bray, F.; Siegel, R. L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. *Ca-Cancer J. Clin.* **2015**, *65* (2), 87–108.

(3) Alberg, A. J.; Brock, M. V.; Ford, J. G.; Samet, J. M.; Spivack, S. D. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* **2013**, *143* (5), e1S–29S.

(4) Pass, H. I., C. D. P., Johnson, D. H., Minna, J. D., Scagliotti, G. V., Turrisi, A. T. *Principles and Practice of Lung Cancer. The Official Reference Text of the IASLC*, 4th ed.; Lippincott Williams & Wilkins: 2010.

(5) Lung Cancer - American Cancer Society. <http://www.cancer.org/cancer/lungcancer/index> (accessed 5 Aug 2016).

(6) DeSantis, C. E.; Lin, C. C.; Mariotto, A. B.; Siegel, R. L.; Stein, K. D.; Kramer, J. L.; et al. Cancer treatment and survivorship statistics, 2014. *Ca-Cancer J. Clin.* **2014**, *64* (4), 252–71.

(7) Alberg, A. J.; Nonemaker, J. Who is at high risk for lung cancer? Population-level and individual-level perspectives. *Semin Respir Crit Care Med.* **2008**, *29* (3), 223–32.

(8) Davidson, M. R.; Gazdar, A. F.; Clarke, B. E. The pivotal role of pathology in the management of lung cancer. *J. Thorac. Dis.* **2013**, *5* (Suppl 5), S463–78.

(9) Kalemkerian, G. P.; Akerley, W.; Bogner, P.; Borghaei, H.; Chow, L.; Downey, R. J.; et al. Small cell lung cancer. *J. Natl. Compr. Cancer Network* **2011**, *9* (10), 1086–113.

(10) Blanchon, T.; Brechot, J. M.; Grenier, P. A.; Ferretti, G. R.; Lemarie, E.; Milleron, B.; et al. Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). *Lung Cancer* **2007**, *58* (1), 50–8.

(11) Gohagan, J. K.; Marcus, P. M.; Fagerstrom, R. M.; Pinsky, P. F.; Kramer, B. S.; Prorok, P. C.; et al. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. *Lung Cancer* **2005**, *47* (1), 9–15.

(12) Goldstraw, P.; Crowley, J.; Chansky, K.; Giroux, D. J.; Groome, P. A.; Rami-Porta, R.; et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. *J. Thorac. Oncol.* **2007**, *2* (8), 706–14.

(13) Henschke, C. I. International Early Lung Cancer Action Program, I, Survival of patients with clinical stage I lung cancer diagnosed by computed tomography screening for lung cancer. *Clin. Cancer Res.* **2007**, *13* (17), 4949–50.

(14) Humphrey, L. L.; Deffebach, M.; Pappas, M.; Baumann, C.; Artis, K.; Mitchell, J. P.; et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. *Ann. Intern. Med.* **2013**, *159* (6), 411–20.

(15) Infante, M.; Cavuto, S.; Lutman, F. R.; Brambilla, G.; Chiesa, G.; Ceresoli, G.; et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. *Am. J. Respir. Crit. Care Med.* **2009**, *180* (5), 445–53.

(16) Infante, M.; Cavuto, S.; Lutman, F. R.; Passera, E.; Chiarenza, M.; Chiesa, G.; et al. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. *Am. J. Respir. Crit. Care Med.* **2015**, *191* (10), 1166–75.

(17) Saghir, Z.; Dirksen, A.; Ashraf, H.; Bach, K. S.; Brodersen, J.; Clementsen, P. F.; et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. *Thorax* **2012**, *67* (4), 296–301.

(18) Pastorino, U.; Rossi, M.; Rosato, V.; Marchiano, A.; Sverzellati, N.; Morosi, C.; et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. *Eur. J. Cancer Prev.* **2012**, *21* (3), 308–15.

(19) Aberle, D. R.; Adams, A. M.; Berg, C. D.; Black, W. C.; Clapp, J. D.; Fagerstrom, R. M.; et al. Reduced lung-cancer mortality with low-

dose computed tomographic screening. *N. Engl. J. Med.* **2011**, 365 (5), 395–409.

(20) Aberle, D. R.; DeMello, S.; Berg, C. D.; Black, W. C.; Brewer, B.; Church, T. R.; et al. Results of the two incidence screenings in the National Lung Screening Trial. *N. Engl. J. Med.* **2013**, 369 (10), 920–31.

(21) Infante, M.; Lutman, F. R.; Cavuto, S.; Brambilla, G.; Chiesa, G.; Passera, E.; et al. Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. *Lung Cancer* **2008**, 59 (3), 355–63.

(22) Lopes Pegna, A.; Picozzi, G.; Mascalchi, M.; Maria Carozzi, F.; Carrozzi, L.; Comin, C.; et al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. *Lung Cancer* **2009**, 64 (1), 34–40.

(23) van Iersel, C. A.; de Koning, H. J.; Draisma, G.; Mali, W. P.; Scholten, E. T.; Nackaerts, K.; et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). *Int. J. Cancer* **2007**, 120 (4), 868–74.

(24) van Klaveren, R. J.; Oudkerk, M.; Prokop, M.; Scholten, E. T.; Nackaerts, K.; Vernhout, R.; et al. Management of lung nodules detected by volume CT scanning. *N. Engl. J. Med.* **2009**, 361 (23), 2221–9.

(25) Horeweg, N.; van der Aalst, C. M.; Vliegenthart, R.; Zhao, Y.; Xie, X.; Scholten, E. T.; et al. Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. *Eur. Respir. J.* **2013**, 42 (6), 1659–67.

(26) Pedersen, J. H.; Ashraf, H.; Dirksen, A.; Bach, K.; Hansen, H.; Toennesen, P.; et al. The Danish randomized lung cancer CT screening trial—overall design and results of the prevalence round. *J. Thorac. Oncol.* **2009**, 4 (5), 608–14.

(27) Becker, N.; Motsch, E.; Gross, M. L.; Eigentopf, A.; Heussel, C. P.; Dienemann, H.; et al. Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the first screening round. *J. Cancer Res. Clin. Oncol.* **2012**, 138 (9), 1475–86.

(28) Becker, N.; Motsch, E.; Gross, M. L.; Eigentopf, A.; Heussel, C. P.; Dienemann, H.; et al. Randomized Study on Early Detection of Lung Cancer with MSCT in Germany: Results of the First 3 Years of Follow-up After Randomization. *J. Thorac. Oncol.* **2015**, 10 (6), 890–6.

(29) Baldwin, D. R.; Duffy, S. W.; Wald, N. J.; Page, R.; Hansell, D. M.; Field, J. K. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. *Thorax* **2011**, 66 (4), 308–13.

(30) Field, J. K.; Duffy, S. W.; Baldwin, D. R.; Whyntes, D. K.; Devaraj, A.; Brain, K. E.; et al. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. *Thorax* **2016**, 71 (2), 161–70.

(31) Horeweg, N.; van der Aalst, C. M.; Thunnissen, E.; Nackaerts, K.; Weenink, C.; Groen, H. J.; et al. Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. *Am. J. Respir. Crit. Care Med.* **2013**, 187 (8), 848–54.

(32) Xu, D. M.; Gietema, H.; de Koning, H.; Vernhout, R.; Nackaerts, K.; Prokop, M.; et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. *Lung Cancer* **2006**, 54 (2), 177–84.

(33) van Meerbeeck, J. P.; Koning, C. C.; Tjan-Heijnen, V. C.; Boekema, A. G.; Kaandorp, C. J.; Burgers, J. S. [Guideline on 'non-small cell lung carcinoma; staging and treatment'] Richtlijn 'Niet-kleincellig longcarcinoom; stadiering en behandeling'. *Ned. Tijdschr. Geneesk.* **2005**, 149 (2), 72–7.

(34) Bach, P. B.; Mirkin, J. N.; Oliver, T. K.; Azzoli, C. G.; Berry, D. A.; Brawley, O. W.; et al. Benefits and harms of CT screening for lung cancer: a systematic review. *JAMA* **2012**, 307 (22), 2418–29.

(35) de Koning, H. J.; Meza, R.; Plevritis, S. K.; ten Haaf, K.; Munshi, V. N.; Jeon, J.; et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. *Ann. Intern. Med.* **2014**, 160 (5), 311–20.

(36) Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. *Cell* **2000**, 100 (1), 57–70.

(37) Wistuba, II; Gazdar, A. F. Lung cancer preneoplasia. *Annu. Rev. Pathol.: Mech. Dis.* **2006**, 1, 331–48.

(38) Larsen, J. E.; Minna, J. D. Molecular biology of lung cancer: clinical implications. *Clin Chest Med.* **2011**, 32 (4), 703–40.

(39) Li, X. J.; Hayward, C.; Fong, P. Y.; Dominguez, M.; Hunsucker, S. W.; Lee, L. W.; et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. *Sci. Transl. Med.* **2013**, 5 (207), 207ra142.

(40) Patz, E. F., Jr.; Campa, M. J.; Gottlin, E. B.; Trotter, P. R.; Herndon, J. E., 2nd; Kafader, D.; et al. Biomarkers to help guide management of patients with pulmonary nodules. *Am. J. Respir. Crit. Care Med.* **2013**, 188 (4), 461–5.

(41) Pecot, C. V.; Li, M.; Zhang, X. J.; Rajanbabu, R.; Calitri, C.; Bungum, A.; et al. Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules. *Cancer Epidemiol., Biomarkers Prev.* **2012**, 21 (5), 786–92.

(42) Bigbee, W. L.; Gopalakrishnan, V.; Weissfeld, J. L.; Wilson, D. O.; Dacic, S.; Lokshin, A. E.; et al. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. *J. Thorac. Oncol.* **2012**, 7 (4), 698–708.

(43) Diamandis, E. P.; Goodglick, L.; Planque, C.; Thornquist, M. D. Pentraxin-3 is a novel biomarker of lung carcinoma. *Clin. Cancer Res.* **2011**, 17 (8), 2395–9.

(44) Takano, A.; Ishikawa, N.; Nishino, R.; Masuda, K.; Yasui, W.; Inai, K.; et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. *Cancer Res.* **2009**, 69 (16), 6694–703.

(45) Ostroff, R. M.; Bigbee, W. L.; Franklin, W.; Gold, L.; Mehan, M.; Miller, Y. E.; et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. *PLoS One* **2010**, 5 (12), e15003.

(46) Patz, E. F., Jr.; Campa, M. J.; Gottlin, E. B.; Kusmartseva, I.; Guan, X. R.; Herndon, J. E., 2nd Panel of serum biomarkers for the diagnosis of lung cancer. *J. Clin. Oncol.* **2007**, 25 (35), 5578–83.

(47) Yildiz, P. B.; Shyr, Y.; Rahman, J. S.; Wardwell, N. R.; Zimmerman, L. J.; Shakhmourad, B.; et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. *J. Thorac. Oncol.* **2007**, 2 (10), 893–901.

(48) Gao, W. M.; Kuick, R.; Orzechowski, R. P.; Misek, D. E.; Qiu, J.; Greenberg, A. K.; et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. *BMC Cancer* **2005**, 5, 110.

(49) Molina, R.; Filella, X.; Auge, J. M.; Fuentes, R.; Bover, I.; Rifa, J.; et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. *Tumor Biol.* **2003**, 24 (4), 209–18.

(50) Barlesi, F.; Gimenez, C.; Torre, J. P.; Doddoli, C.; Mancini, J.; Greillier, L.; et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. *Respir Med.* **2004**, 98 (4), 357–62.

(51) Anderson, N.; Anderson, N. The human plasma proteome: history, character, and diagnostic prospects. *Mol. Cell. Proteomics* **2002**, 1, 845–67.

(52) Anderson, K. S.; LaBaer, J. The sentinel within: exploiting the immune system for cancer biomarkers. *J. Proteome Res.* **2005**, 4 (4), 1123–33.

(53) Qiu, J.; Hanash, S. Autoantibody profiling for cancer detection. *Clin Lab Med.* **2009**, 29 (1), 31–46.

(54) Dunn, G. P.; Old, L. J.; Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. *Immunity* **2004**, 21 (2), 137–48.

(55) Finn, O. J. Cancer immunology. *N. Engl. J. Med.* **2008**, 358 (25), 2704–15.

- (56) Caron, M.; Choquet-Kastylevsky, G.; Joubert-Caron, R. Cancer immunomics using autoantibody signatures for biomarker discovery. *Mol. Cell. Proteomics* **2007**, *6* (7), 1115–22.
- (57) Backes, C.; Ludwig, N.; Leidinger, P.; Harz, C.; Hoffmann, J.; Keller, A.; et al. Immunogenicity of autoantigens. *BMC Genomics* **2011**, *12*, 340.
- (58) Hanash, S. Harnessing immunity for cancer marker discovery. *Nat. Biotechnol.* **2003**, *21* (1), 37–8.
- (59) Tan, H. T.; Low, J.; Lim, S. G.; Chung, M. C. Serum autoantibodies as biomarkers for early cancer detection. *FEBS J.* **2009**, *276* (23), 6880–904.
- (60) Zhong, L.; Coe, S. P.; Stromberg, A. J.; Khattar, N. H.; Jett, J. R.; Hirschowitz, E. A. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. *J. Thorac. Oncol.* **2006**, *1* (6), 513–9.
- (61) Chapman, C. J.; Murray, A.; McElveen, J. E.; Sahin, U.; Luxemburger, U.; Tureci, O.; et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. *Thorax* **2008**, *63* (3), 228–33.
- (62) Finn, O. J. Immune response as a biomarker for cancer detection and a lot more. *N. Engl. J. Med.* **2005**, *353* (12), 1288–90.
- (63) Tonegawa, S. Reiteration frequency of immunoglobulin light chain genes: further evidence for somatic generation of antibody diversity. *Proc. Natl. Acad. Sci. U. S. A.* **1976**, *73* (1), 203–7.
- (64) de Wildt, R. M.; van Venrooij, W. J.; Winter, G.; Hoet, R. M.; Tomlinson, I. M. Somatic insertions and deletions shape the human antibody repertoire. *J. Mol. Biol.* **1999**, *294* (3), 701–10.
- (65) Meffre, E.; Catalan, N.; Seltz, F.; Fischer, A.; Nussenzweig, M. C.; Durandy, A. Somatic hypermutation shapes the antibody repertoire of memory B cells in humans. *J. Exp. Med.* **2001**, *194* (3), 375–8.
- (66) Murphy, K.; Travers, P.; Walport, M. *Janeway's Immunobiology*, 7th ed.; Garland Science: 2008.
- (67) Schroeder, H. W., Jr.; Cavacini, L. Structure and function of immunoglobulins. *J. Allergy Clin. Immunol.* **2010**, *125* (2), S41–52.
- (68) Xu, J. L.; Davis, M. M. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. *Immunity* **2000**, *13* (1), 37–45.
- (69) Saada, R.; Weinberger, M.; Shahaf, G.; Mehr, R. Models for antigen receptor gene rearrangement: CDR3 length. *Immunol. Cell Biol.* **2007**, *85* (4), 323–32.
- (70) Baranzini, S. E.; Jeong, M. C.; Butunoi, C.; Murray, R. S.; Bernard, C. C.; Oksenberg, J. R. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. *J. Immunol.* **1999**, *163* (9), 5133–44.
- (71) Andersen, P. S.; Haahr-Hansen, M.; Coljee, V. W.; Hinnerfeldt, F. R.; Varming, K.; Bregenholt, S.; et al. Extensive restrictions in the VH sequence usage of the human antibody response against the Rhesus D antigen. *Mol. Immunol.* **2007**, *44* (4), 412–22.
- (72) Wang, J.; Shivakumar, S.; Barker, K.; Tang, Y.; Wallstrom, G.; Park, J. G.; et al. Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules. *J. Thorac. Oncol.* **2016**, *11* (3), 334–45.
- (73) Doseeva, V.; Colpitts, T.; Gao, G.; Woodcock, J.; Knezevic, V. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer. *J. Transl. Med.* **2015**, *13*, 55.
- (74) Jett, J. R.; Peek, L. J.; Fredericks, L.; Jewell, W.; Pingleton, W. W.; Robertson, J. F. Audit of the autoantibody test, EarlyCDT(R)-lung, in 1600 patients: an evaluation of its performance in routine clinical practice. *Lung Cancer* **2014**, *83* (1), 51–5.
- (75) Jia, J.; Wang, W.; Meng, W.; Ding, M.; Ma, S.; Wang, X. Development of a multiplex autoantibody test for detection of lung cancer. *PLoS One* **2014**, *9* (4), e95444.
- (76) Wang, W.; Guan, S.; Sun, S.; Jin, Y.; Lee, K. H.; Chen, Y.; et al. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer. *Tumor Biol.* **2014**, *35* (5), 4901–5.
- (77) Lowe, F. J.; Shen, W.; Zu, J.; Li, J.; Wang, H.; Zhang, X.; et al. A novel autoantibody test for the detection of pre-neoplastic lung lesions. *Mol. Cancer* **2014**, *13*, 78.
- (78) Zhang, C.; Ye, L.; Guan, S.; Jin, S.; Wang, W.; Sun, S.; et al. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer. *Tumor Biol.* **2014**, *35* (3), 2047–51.
- (79) Pedchenko, T.; Mernaugh, R.; Parekh, D.; Li, M.; Massion, P. P. Early detection of NSCLC with scFv selected against IgM autoantibody. *PLoS One* **2013**, *8* (4), e60934.
- (80) Chapman, C. J.; Healey, G. F.; Murray, A.; Boyle, P.; Robertson, C.; Peek, L. J.; et al. EarlyCDT(R)-Lung test: improved clinical utility through additional autoantibody assays. *Tumor Biol.* **2012**, *33* (5), 1319–26.
- (81) Lam, S.; Boyle, P.; Healey, G. F.; Maddison, P.; Peek, L.; Murray, A.; et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. *Cancer Prev. Res.* **2011**, *4* (7), 1126–34.
- (82) Boyle, P.; Chapman, C. J.; Holdenrieder, S.; Murray, A.; Robertson, C.; Wood, W. C.; et al. Clinical validation of an autoantibody test for lung cancer. *Ann. Oncol.* **2011**, *22* (2), 383–9.
- (83) Rom, W. N.; Goldberg, J. D.; Addrizzo-Harris, D.; Watson, H. N.; Khilkin, M.; Greenberg, A. K.; et al. Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. *BMC Cancer* **2010**, *10*, 234.
- (84) Farlow, E. C.; Patel, K.; Basu, S.; Lee, B. S.; Kim, A. W.; Coon, J. S.; et al. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. *Clin. Cancer Res.* **2010**, *16* (13), 3452–62.
- (85) Yao, X.; Jiang, H.; Zhang, C.; Wang, H.; Yang, L.; Yu, Y.; et al. Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer. *Biomarkers* **2010**, *15* (2), 128–34.
- (86) Wu, L.; Chang, W.; Zhao, J.; Yu, Y.; Tan, X.; Su, T.; et al. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. *Clin. Cancer Res.* **2010**, *16* (14), 3760–8.
- (87) Leidinger, P.; Keller, A.; Heisel, S.; Ludwig, N.; Rheinheimer, S.; Klein, V.; et al. Identification of lung cancer with high sensitivity and specificity by blood testing. *Respir. Res.* **2010**, *11*, 18.
- (88) Murray, A.; Chapman, C. J.; Healey, G.; Peek, L. J.; Parsons, G.; Baldwin, D.; et al. Technical validation of an autoantibody test for lung cancer. *Ann. Oncol.* **2010**, *21* (8), 1687–93.
- (89) Qiu, J.; Choi, G.; Li, L.; Wang, H.; Pitteri, S. J.; Pereira-Faca, S. R.; et al. Occurrence of autoantibodies to annexin I, 14–3-3 theta and LAMR1 in prediagnostic lung cancer sera. *J. Clin. Oncol.* **2008**, *26* (31), 5060–6.
- (90) Leidinger, P.; Keller, A.; Ludwig, N.; Rheinheimer, S.; Hamacher, J.; Huwer, H.; et al. Toward an early diagnosis of lung cancer: an autoantibody signature for squamous cell lung carcinoma. *Int. J. Cancer* **2008**, *123* (7), 1631–6.
- (91) Pereira-Faca, S. R.; Kuick, R.; Puravs, E.; Zhang, Q.; Krasnoselsky, A. L.; Phanstiel, D.; et al. Identification of 14–3-3 theta as an antigen that induces a humoral response in lung cancer. *Cancer Res.* **2007**, *67* (24), 12000–6.
- (92) Yagihashi, A.; Asanuma, K.; Kobayashi, D.; Tsuji, N.; Shijubo, Y.; Abe, S.; et al. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. *Lung Cancer* **2005**, *48* (2), 217–21.
- (93) Foreman, A. L.; Lemerrier, B.; Lim, A.; Kourlisky, P.; Kenny, T.; Gershwin, M. E.; et al. VH gene usage and CDR3 analysis of B cell receptor in the peripheral blood of patients with PBC. *Autoimmunity* **2008**, *41* (1), 80–6.
- (94) Weinstein, J. A.; Jiang, N.; White, R. A., 3rd; Fisher, D. S.; Quake, S. R. High-throughput sequencing of the zebrafish antibody repertoire. *Science* **2009**, *324* (5928), 807–10.
- (95) VanDuijn, M. M.; Dekker, L. J.; Zeneyedpour, L.; Smitt, P. A.; Luidert, T. M. Immune responses are characterized by specific shared immunoglobulin peptides that can be detected by proteomic techniques. *J. Biol. Chem.* **2010**, *285* (38), 29247–53.
- (96) Scheid, J. F.; Mouquet, H.; Ueberheide, B.; Diskin, R.; Klein, F.; Oliveira, T. Y.; et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. *Science* **2011**, *333* (6049), 1633–7.

(97) Maat, P.; Vanduijn, M.; Brouwer, E.; Dekker, L.; Zeneyedpour, L.; Luidar, T.; et al. Mass spectrometric detection of antigen-specific immunoglobulin peptides in paraneoplastic patient sera. *J. Autoimmun.* **2012**, *38*, 354.

(98) de Costa, D.; Broodman, I.; Calame, W.; Stingl, C.; Dekker, L. J.; Vernhout, R. M.; et al. Peptides from the variable region of specific antibodies are shared among lung cancer patients. *PLoS One* **2014**, *9* (5), e96029.

(99) Tsybin, Y. O.; Fornelli, L.; Stoermer, C.; Luebeck, M.; Parra, J.; Nallet, S.; et al. Structural analysis of intact monoclonal antibodies by electron transfer dissociation mass spectrometry. *Anal. Chem.* **2011**, *83* (23), 8919–27.

(100) Dekker, L.; Wu, S.; Vanduijn, M.; Tolic, N.; Stingl, C.; Zhao, R.; et al. An integrated top-down and bottom-up proteomic approach to characterize the antigen-binding fragment of antibodies. *Proteomics* **2014**, *14* (10), 1239–48.

(101) Alfaro, J. A.; Sinha, A.; Kislinger, T.; Boutros, P. C. Onco-proteogenomics: cancer proteomics joins forces with genomics. *Nat. Methods* **2014**, *11* (11), 1107–13.

(102) Nagaraj, S. H.; Waddell, N.; Madugundu, A. K.; Wood, S.; Jones, A.; Mandyam, R. A.; et al. PGTools: A Software Suite for Proteogenomic Data Analysis and Visualization. *J. Proteome Res.* **2015**, *14* (5), 2255–66.

(103) Benichou, J.; Ben-Hamo, R.; Louzoun, Y.; Efroni, S. Rep-Seq: uncovering the immunological repertoire through next-generation sequencing. *Immunology* **2012**, *135* (3), 183–91.

(104) Greiff, V.; Menzel, U.; Haessler, U.; Cook, S. C.; Friedensohn, S.; Khan, T. A.; et al. Quantitative assessment of the robustness of next-generation sequencing of antibody variable gene repertoires from immunized mice. *BMC Immunol.* **2014**, *15*, 40.